# Obesity biotech Alveus gains $160M for push into MariTide's backyard — and amylins

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wxihdk-jykykhhuld-k/
**Date:** 2026-01-09

---

Alveus Therapeutics CEO Raj Kannan (L) and CSO Jacob Jeppesen

January 8, 2026 07:30 AM EST FinancingStartups

Obe­si­ty biotech Alveus gains $160M for push in­to Mar­i­Tide's back­yard — and amylins

Kyle LaHucik

Biotech Correspondent

An­oth­er obe­si­ty biotech has en­tered the fray as tirzepatide and semaglu­tide fly off phar­ma­cy shelves.

Alveus Ther­a­peu­tics dis­closed a $159.8 mil­lion Se­ries A on Thurs­day …

---

#news #endpoints-news
